Division of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
Crit Rev Oncol Hematol. 2011 Nov;80(2):225-40. doi: 10.1016/j.critrevonc.2010.12.001. Epub 2011 Jan 13.
Toll-like receptors are critical structures in sensing the invading pathogens via conserved moieties termed pathogen associated molecular patterns and in directing the innate and adaptive immune responses. Studies have shown that Toll-like receptors are not limited to normal immune cells but are expressed on tumour cells as well, including those of lymphoid neoplasms particularly B-cell malignancies, multiple myeloma and chronic lymphocytic leukemia. Neoplastic plasma cells in multiple myeloma usually show a different pattern of Toll-like receptor expression compared to normal B cells. These receptors on multiple myeloma cells, have been indicated to have a role in their proliferation, differentiation and survival, probably through induction of autocrine IL-6 secretion, and in their immunomodulatory functions. Moreover, it is speculated that these molecules may contribute to osteolytic lesions through activation of osteoclasts, and to angiogenesis through induction of pro-angiogenic factors. Knowledge on Toll-like receptor signalling in the biology of malignant plasma cells or their cellular microenvironment may give new insights into pathogenesis of multiple myeloma and may open new avenues for the therapy of this disease.
Toll 样受体是通过保守的称为病原体相关分子模式的结构来感知入侵病原体的关键结构,并指导先天和适应性免疫反应。研究表明,Toll 样受体不仅局限于正常免疫细胞,而且也在肿瘤细胞上表达,包括淋巴细胞肿瘤,特别是 B 细胞恶性肿瘤、多发性骨髓瘤和慢性淋巴细胞白血病。多发性骨髓瘤中的肿瘤浆细胞通常表现出与正常 B 细胞不同的 Toll 样受体表达模式。这些多发性骨髓瘤细胞上的受体在其增殖、分化和存活中发挥作用,可能通过诱导自分泌 IL-6 分泌,并发挥其免疫调节功能。此外,据推测,这些分子可能通过激活破骨细胞导致溶骨性病变,并通过诱导促血管生成因子导致血管生成。对恶性浆细胞生物学或其细胞微环境中的 Toll 样受体信号的了解可能会深入了解多发性骨髓瘤的发病机制,并为这种疾病的治疗开辟新的途径。